Cyrus Bakhit, MD
Interventional Pain Medicine · Roanoke, VANPI 1548295165
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Medtronic at 30.8% of the total.
Across 410 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Collegium Pharmaceutical, Inc.$916
- AbbVie$915
- Nevro Corp.$688
- Abbott$680
- IBSA Pharma Inc.$460
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1922%
- Food & beverage$7,56898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 94 | $2,390 |
| Collegium Pharmaceutical, Inc. | 77 | $916 |
| AbbVie(2 entities) | 69 | $915 |
| Nevro Corp. | 36 | $688 |
| Abbott | 45 | $680 |
| IBSA Pharma Inc. | 17 | $460 |
| Johnson & Johnson | 18 | $290 |
| Stimwave Technologies Incorporated | 2 | $202 |
| Spinal Simplicity, LLC | 1 | $197 |
| Pfizer | 8 | $143 |
| Si-bone, Inc. | 6 | $133 |
| GRT US Holding, Inc. | 6 | $125 |
| Amgen | 4 | $91 |
| Boston Scientific | 3 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $76 |
| Bioventus LLC | 3 | $48 |
| Fidia Pharma USA Inc. | 2 | $41 |
| USWM, LLC | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $32 |
| Vertex | 1 | $26 |
| MDD US Operations, LLC | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Metacel Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$241
- HA MINUTEMAN G3-R$197
- StimQ Receiver Stimulator Kit Channel A US w Receiver$192
- StimQ Freedom 4A Receiver Kit Channel A US Receiver$192
- StimQ Freedom 8A Receiver Kit Channel A US w Receiver$192
- Freedom 4A Receiver Kit Channel A US w Receiver$192
- Freedom 8A Receiver Kit Channel A US w Receiver$192
- Accurian$175
- VANTA ADAPTIVESTIM$129
- SYNCHROMEDII$126
- INTELLIS$105
How this compares
$7,760 in reported general payments places this provider in the 65th percentile of 52 interventional pain medicine providers in Virginia.
See all interventional pain medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 88 | $77,606 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,565 | $64,577 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,946 | $61,920 |
| Buprenorphine | 226 | $57,390 |
| UbrelvyUbrogepant | 23 | $47,196 |
| Oxycodone Hcl | 2,236 | $46,908 |
| Xtampza ErOxycodone Myristate | 83 | $46,050 |
| OxycontinOxycodone Hcl | 98 | $43,384 |
| LinzessLinaclotide | 72 | $38,073 |
| QuliptaAtogepant | 29 | $31,352 |
| Fentanyl | 123 | $26,707 |
| Lidocaine | 259 | $25,813 |
| Gabapentin | 2,071 | $25,765 |
| Pregabalin | 703 | $19,544 |
| BotoxOnabotulinumtoxina | 15 | $19,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $916 | $136,570191 claims |
| AbbVieUbrelvy, Linzess, Qulipta, Botox | $915 | $135,691139 claims |
| IBSA Pharma Inc.Licart | $460 | $4,25911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 52 interventional pain medicine providers in Virginia.
Other interventional pain medicine in Roanoke
- Ketan PatelHaymarket$133K
- Che TorryNewport News$48K
- Niteesh BhararaReston$25K
- Sassan HassassianManassas$24K
- Raj SurejaNewport News$23K
- Benjamin SeemanRichmond$21K
- Alok GopalWinchester$16K
- Jacob LeeWinchester$14K
- Yaoming GuRichmond$13K
- Rae DavisLansdowne$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.